To explore a potential explanation for the opposite effects of PGSAUD in COGA EA and the Indiana Biobank cohorts, we conducted exploratory analyses. Since liver diseases are likely attributable in large part to chronic alcohol use and are a significant cause of morbidity and mortality, we calculated the prevalence of liver disease in all study samples. As shown in Table 4, 46.22%−78.33% of Indiana Biobank participants reported the presence of liver diseases in contrast to 3.78%−8.01% of COGA participants reported having liver diseases. The prevalence of liver diseases was markedly higher among remitted participants than those with current AUD in both Indiana Biobank cohorts, with a smaller difference between remitted participants and those with current AUD in COGA EA.
